PortalPublikationenTowards clinical breakpoints for non-tuberculous mycobacteri...

Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution

Standard

Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution. / Fröberg, Gabrielle; Maurer, Florian P; Chryssanthou, Erja; Fernström, Louise; Benmansour, Hanaa; Boarbi, Samira; Mengshoel, Anne Torunn; Keller, Peter Michael; Viveiros, Miguel; Machado, Diana; Fitzgibbon, Margaret M; Mok, Simone; Werngren, Jim; Cirillo, Daniela Maria; Alcaide, Fernando; Hyyryläinen, Hanne-Leena; Aubry, Alexandra; Andres, Sönke; Nadarajan, Darshaalini; Svensson, Erik; Turnidge, John; Giske, Christian G; Kahlmeter, Gunnar; Cambau, Emmanuelle; van Ingen, Jakko; Schön, Thomas; EUCAST AMST and ESCMYC study groups.

in: CLIN MICROBIOL INFEC, Jahrgang 29, Nr. 6, 06.2023, S. 758-764.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Fröberg, G, Maurer, FP, Chryssanthou, E, Fernström, L, Benmansour, H, Boarbi, S, Mengshoel, AT, Keller, PM, Viveiros, M, Machado, D, Fitzgibbon, MM, Mok, S, Werngren, J, Cirillo, DM, Alcaide, F, Hyyryläinen, H-L, Aubry, A, Andres, S, Nadarajan, D, Svensson, E, Turnidge, J, Giske, CG, Kahlmeter, G, Cambau, E, van Ingen, J, Schön, T & EUCAST AMST and ESCMYC study groups 2023, 'Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution', CLIN MICROBIOL INFEC, Jg. 29, Nr. 6, S. 758-764. https://doi.org/10.1016/j.cmi.2023.02.007

APA

Fröberg, G., Maurer, F. P., Chryssanthou, E., Fernström, L., Benmansour, H., Boarbi, S., Mengshoel, A. T., Keller, P. M., Viveiros, M., Machado, D., Fitzgibbon, M. M., Mok, S., Werngren, J., Cirillo, D. M., Alcaide, F., Hyyryläinen, H-L., Aubry, A., Andres, S., Nadarajan, D., ... EUCAST AMST and ESCMYC study groups (2023). Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution. CLIN MICROBIOL INFEC, 29(6), 758-764. https://doi.org/10.1016/j.cmi.2023.02.007

Vancouver

Fröberg G, Maurer FP, Chryssanthou E, Fernström L, Benmansour H, Boarbi S et al. Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution. CLIN MICROBIOL INFEC. 2023 Jun;29(6):758-764. https://doi.org/10.1016/j.cmi.2023.02.007

Bibtex

@article{0c94e8fbec45438db88cb5fd69070d12,
title = "Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution",
abstract = "OBJECTIVE: For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints.METHODS: We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains.RESULTS: The clarithromycin ECOFF was 16 mg/L for M. avium (n = 1271) whereas TECOFFs were 8 mg/L for M. intracellulare (n = 415) and 1 mg/L for MAB (n = 1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n = 235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned >8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M. avium and M. intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M. avium and M. peregrinum, ≥95% of MIC values were well within recommended QC ranges.CONCLUSION: As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs.",
keywords = "Humans, Mycobacterium avium Complex, Anti-Bacterial Agents/pharmacology, Nontuberculous Mycobacteria, Amikacin/pharmacology, Mycobacterium abscessus, Moxifloxacin/pharmacology, Linezolid/pharmacology, Mycobacterium avium-intracellulare Infection/microbiology, Microbial Sensitivity Tests, Drug Resistance, Bacterial, Macrolides/pharmacology, Mycobacterium tuberculosis, Mycobacterium Infections, Nontuberculous/drug therapy, Mycobacterium avium",
author = "Gabrielle Fr{\"o}berg and Maurer, {Florian P} and Erja Chryssanthou and Louise Fernstr{\"o}m and Hanaa Benmansour and Samira Boarbi and Mengshoel, {Anne Torunn} and Keller, {Peter Michael} and Miguel Viveiros and Diana Machado and Fitzgibbon, {Margaret M} and Simone Mok and Jim Werngren and Cirillo, {Daniela Maria} and Fernando Alcaide and Hanne-Leena Hyyryl{\"a}inen and Alexandra Aubry and S{\"o}nke Andres and Darshaalini Nadarajan and Erik Svensson and John Turnidge and Giske, {Christian G} and Gunnar Kahlmeter and Emmanuelle Cambau and {van Ingen}, Jakko and Thomas Sch{\"o}n and {EUCAST AMST and ESCMYC study groups}",
note = "Copyright {\textcopyright} 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.",
year = "2023",
month = jun,
doi = "10.1016/j.cmi.2023.02.007",
language = "English",
volume = "29",
pages = "758--764",
journal = "CLIN MICROBIOL INFEC",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "6",

}

RIS

TY - JOUR

T1 - Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution

AU - Fröberg, Gabrielle

AU - Maurer, Florian P

AU - Chryssanthou, Erja

AU - Fernström, Louise

AU - Benmansour, Hanaa

AU - Boarbi, Samira

AU - Mengshoel, Anne Torunn

AU - Keller, Peter Michael

AU - Viveiros, Miguel

AU - Machado, Diana

AU - Fitzgibbon, Margaret M

AU - Mok, Simone

AU - Werngren, Jim

AU - Cirillo, Daniela Maria

AU - Alcaide, Fernando

AU - Hyyryläinen, Hanne-Leena

AU - Aubry, Alexandra

AU - Andres, Sönke

AU - Nadarajan, Darshaalini

AU - Svensson, Erik

AU - Turnidge, John

AU - Giske, Christian G

AU - Kahlmeter, Gunnar

AU - Cambau, Emmanuelle

AU - van Ingen, Jakko

AU - Schön, Thomas

AU - EUCAST AMST and ESCMYC study groups

N1 - Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2023/6

Y1 - 2023/6

N2 - OBJECTIVE: For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints.METHODS: We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains.RESULTS: The clarithromycin ECOFF was 16 mg/L for M. avium (n = 1271) whereas TECOFFs were 8 mg/L for M. intracellulare (n = 415) and 1 mg/L for MAB (n = 1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n = 235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned >8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M. avium and M. intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M. avium and M. peregrinum, ≥95% of MIC values were well within recommended QC ranges.CONCLUSION: As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs.

AB - OBJECTIVE: For non-tuberculous mycobacteria (NTM), minimum inhibitory concentration (MIC) distributions of wild-type isolates have not been systematically evaluated despite their importance for establishing antimicrobial susceptibility testing (AST) breakpoints.METHODS: We gathered MIC distributions for drugs used against the Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB) obtained by commercial broth microdilution (SLOMYCOI and RAPMYCOI) from 12 laboratories. Epidemiological cut-off values (ECOFFs) and tentative ECOFFs (TECOFFs) were determined by EUCAST methodology including quality control (QC) strains.RESULTS: The clarithromycin ECOFF was 16 mg/L for M. avium (n = 1271) whereas TECOFFs were 8 mg/L for M. intracellulare (n = 415) and 1 mg/L for MAB (n = 1014) confirmed by analysing MAB subspecies without inducible macrolide resistance (n = 235). For amikacin, the ECOFFs were 64 mg/L for MAC and MAB. For moxifloxacin, the WT spanned >8 mg/L for both MAC and MAB. For linezolid, the ECOFF and TECOFF were 64 mg/L for M. avium and M. intracellulare, respectively. Current CLSI breakpoints for amikacin (16 mg/L), moxifloxacin (1 mg/L) and linezolid (8 mg/L) divided the corresponding WT distributions. For QC M. avium and M. peregrinum, ≥95% of MIC values were well within recommended QC ranges.CONCLUSION: As a first step towards clinical breakpoints for NTM, (T)ECOFFs were defined for several antimicrobials against MAC and MAB. Broad wild-type MIC distributions indicate a need for further method refinement which is now under development within the EUCAST subcommittee for anti-mycobacterial drug susceptibility testing. In addition, we showed that several CLSI NTM breakpoints are not consistent in relation to the (T)ECOFFs.

KW - Humans

KW - Mycobacterium avium Complex

KW - Anti-Bacterial Agents/pharmacology

KW - Nontuberculous Mycobacteria

KW - Amikacin/pharmacology

KW - Mycobacterium abscessus

KW - Moxifloxacin/pharmacology

KW - Linezolid/pharmacology

KW - Mycobacterium avium-intracellulare Infection/microbiology

KW - Microbial Sensitivity Tests

KW - Drug Resistance, Bacterial

KW - Macrolides/pharmacology

KW - Mycobacterium tuberculosis

KW - Mycobacterium Infections, Nontuberculous/drug therapy

KW - Mycobacterium avium

U2 - 10.1016/j.cmi.2023.02.007

DO - 10.1016/j.cmi.2023.02.007

M3 - SCORING: Journal article

C2 - 36813087

VL - 29

SP - 758

EP - 764

JO - CLIN MICROBIOL INFEC

JF - CLIN MICROBIOL INFEC

SN - 1198-743X

IS - 6

ER -